Search Results
Your search for it matches 15947 pages
Showing 15401 - 15450Receiving Chemotherapy After a Breast Cancer Diagnosis May Affect a Patient’s Long-Term Employment
A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, the findings by Jagsi et al support efforts to reduce the side effects and burden of...
First-Generation EGFR Tyrosine Kinase Inhibitors Associated With Poorer Progression-Free Survival vs Conventional Chemotherapy in EGFR Wild-Type NSCLC
Activating EGFR mutations are found in approximately 10% of Western patients and 50% of Asian patients with non–small cell lung cancer (NSCLC), and EGFR tyrosine kinase inhibitors are recommended for use in first-line treatment in this setting. Both tyrosine kinase inhibitors and cytotoxic...
FDA Approves First HPV Test for Primary Cervical Cancer Screening
The U.S. Food and Drug Administration (FDA) today approved the first human papillomavirus (HPV) DNA test that can be used as a primary cervical cancer screening test for women aged 25 years and older. The test also can provide information about the patient’s risk for developing cervical...
Researchers Identify Pathway That Drives Development of Cancer 'Stemness' and Drug Resistance
Most drugs used to treat lung, breast, and pancreatic cancers also promote drug resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego, School of Medicine have discovered a biomarker called CD61 on the surface of drug-resistant tumors that may be...
FDA Approves Ramucirumab for Stomach Cancer
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy....
Researchers Uncover Link Between Down Syndrome and Leukemia
Although doctors have long known that people with Down syndrome have a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood, they haven’t been able to explain why. In a new study published online in Nature Genetics, Lane et al tracked the genetic chain of events...
FDA Discourages Use of Laparoscopic Power Morcellation for Removal of Uterus or Uterine Fibroids
In a safety communication notice issued yesterday, the U.S. Food and Drug Administration (FDA) discouraged the use of laparoscopic power morcellation for the removal of the uterus (hysterectomy) or uterine fibroids (myomectomy) in women because, based on an analysis of currently available data, it...
Quality-of-Life Study in NCIC MAP.3 Trial Shows Limited Negative Impact of Daily Exemestane in Breast Cancer Prevention
The National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial showed that daily exemestane treatment reduced invasive breast cancer risk by 65% among postmenopausal women. In a quality-of-life study in the MAP.3 population reported in the Journal of...
Study Finds a Quarter of Men Drop Out of Prostate Cancer Monitoring, Casting Doubt on Safety of Active Surveillance
Noncompliance appears to be a major challenge for active surveillance, according to the results of long-term follow-up of patients with prostate cancer presented at the European Association of Urology 29th Annual Congress in Stockholm. Over a quarter of men dropped out of the active surveillance...
Novel Blood-Based Biomarkers May Predict Breast Cancer Recurrence and Treatment Response
Researchers have developed a quantitative multiplexed methylation-specific polymerase chain reaction assay called cMethDNA for a panel of 10 breast cancer–specific genes. The blood-based assay was found to be highly sensitive in detecting advanced breast cancer and monitoring tumor burden and ...
ASCO Issues Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer
ASCO has adapted the Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer for use in the screening, assessment, and care of anxiety and depressive symptoms in adults with cancer. The adapted guideline, reported in...
ASCO Releases Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
The American Society of Clinical Oncology has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology. The overall incidence of chemotherapy-induced peripheral neuropathy ...
Study Examines Protein Expression Biomarkers in HPV-Negative Squamous Cell Carcinomas of the Head and Neck
A quartet of proteins that play critical roles in cell replication, cell death, and DNA repair could lead to better targets for therapy against treatment-resistant head and neck squamous cell cancers. In a study presented this week at the American Association for Cancer Research (AACR) Annual...
IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Russell et al found that immunoglobulin heavy chain (IGH@) translocations were present in a substantial proportion of younger patients with acute lymphoblastic leukemia (ALL), including those with B-cell precursor ALL. However, IGH@...
ASCO Endorses SSO/ASTRO Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer
As reported in the Journal of Clinical Oncology by Buchholz et al, ASCO has endorsed the recently published Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stage I...
Phase II Study Suggests Promise of Intermittent Chemotherapy Plus Continuous Cetuximab in Advanced KRAS Wild-Type Colorectal Cancer
In a phase II study (COIN-B) reported in The Lancet Oncology, Wasan et al examined the addition of continuous or intermittent cetuximab (Erbitux) to intermittent chemotherapy in previously untreated advanced KRAS wild-type colorectal cancer. Continuous cetuximab appeared to be associated with...
Six Months Hormonal Treatment in Addition to Radiotherapy Improves Survival for Men With Localized Prostate Cancer
Men with localized prostate cancer that is at risk of growing and spreading have a lower risk of disease progression and recurrence if they are treated with radiotherapy combined with androgen-deprivation therapy, according to new research. The findings, which were presented at the 33rd Conference...
Experimental Drug Shows Promise for Treatment-Resistant Leukemia
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. The study by Ma et al, published in Blood, found that ...
High Prediagnosis BMI Is a Predictor for Poor Outcome in Colorectal Cancer Patients, Overriding Tumor Marker Linked to Better Prognosis
A large prospective study of patients with invasive colorectal cancer has found that higher body mass index 2 years before diagnosis increased risk of all-cause mortality after diagnosis, even in patients whose tumors harbored a marker that is usually associated with better prognosis. The...
Preclinical Study Identifies Potential New Approach to Overcome Breast Cancer Resistance to HER2-Targeted Therapies
Resistance to a combination of HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), was associated with elevated activation of a group of proteins called fibroblast growth factor receptors (FGFRs), which are the target of a number of drugs currently being developed, according to ...
Study Identifies Potential Predictor of Clinical Outcome in Patients With Lung Cancer Treated With MK-3475
Among patients with non–small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes, according to results of a phase I clinical trial presented at the American...
Prognosis of HPV-Positive Head and Neck Cancer Varies According to Tumor Site
Patients with cancer of the throat and who are positive for the human papillomavirus (HPV) have a good prognosis, but until now the effect of being HPV-positive on the prognosis of tumors located elsewhere in the head and neck was unknown. A new study presented at the 33rd Conference of the...
New Test Developed to Detect Men at High Risk of Prostate Cancer Recurrence
A new genetic signature to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, according to a study presented at the 33rd Conference of the European Society for Radiotherapy and Oncology in...
I-SPY 2 Results Identify Subset of Breast Cancer Patients Most Likely to Benefit From Neratinib
Findings from the I-SPY 2 randomized phase II clinical trial for women with newly diagnosed stage II breast cancer show that a neoadjuvant regimen containing the investigational drug neratinib, a pan-HER inhibitor, and standard chemotherapy is beneficial for patients with hormone...
Biomarker Identifies Melanoma Patients Who May Respond to Immunotherapy MK-3475
Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego. When the protein...
High t(14;18) Translocation Frequency Predicts Follicular Lymphoma up to 15 Years Later
The t(14;18) translocation is a hallmark and critical event in the development of follicular lymphoma, but it is also detectable in otherwise healthy persons, and its relationship to progression to disease is unclear. In a study reported in the Journal of Clinical Oncology, Roulland et al found...
Tumor-Suppressor Gene TP53 Mutated in 90% of Osteosarcomas
The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project found mutations in the tumor-suppressor gene TP53 in 90% of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer. The study by Chen et al was...
Validation of Mantle Cell Lymphoma International Prognostic Index in European Mantle Cell Lymphoma Network Trials
The Mantle Cell Lymphoma International Prognostic Index (MIPI) was developed in 2008 as the first prognostic stratification system specific for mantle cell lymphoma (MCL). In a study reported in the Journal of Clinical Oncology, Hoster et al confirmed the validity of MIPI in a cohort of two...
HLA Class I Antigen Expression Predicts Overall Survival Benefit With Aspirin Use in Colon Cancer
In a cohort study reported in JAMA Internal Medicine, Reimers et al found that aspirin use was associated with a significant 47% reduction in mortality risk after diagnosis of colon cancer expressing HLA class I antigen. There was no difference in aspirin benefit according to strong or weak...
Findings of AURELIA Trial Support Consideration of Bevacizumab/Chemotherapy in Carefully Selected Patients With Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvements in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Study Finds Chemotherapy Accelerates Molecular Aging in Patients With Breast Cancer
Physicians have long suspected that chemotherapy can accelerate the aging process in patients treated for cancer. Using a test developed at UNC Lineberger Comprehensive Cancer Center to determine molecular aging, oncologists have directly measured the impact of anticancer chemotherapy drugs on...
Experts Call for More Awareness of Sexual Dysfunction in Lung Cancer Patients
Many lung cancer patients suffer difficulties with sexual expression and intimacy, yet for too long the topic has been ignored by doctors and researchers, experts said at the 4th European Lung Cancer Conference (ELCC) in Geneva, Switzerland. Researchers have estimated that sexual dysfunction...
FDA Panel Endorses Stool-Based DNA Colon Cancer Test
The U.S. Food and Drug Administration’s (FDA) committee of genetic experts has determined that Cologuard, a stool-based DNA, noninvasive screening test for colorectal cancer, has demonstrated safety, effectiveness, and a favorable risk-benefit profile. The FDA is now considering the...
Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment
Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...
Gene Implicated in Progression and Relapse of Triple-Negative Breast Cancer
Scientists from Weill Cornell Medical College, New York, and Houston Methodist, Houston, have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple-negative form of the disease. The research by Chen et al, published in Nature,...
Omitting Radiotherapy in Early PET-Negative Stage I/II Hodgkin Lymphoma Is Associated With Increased Risk of Early Relapse
The EORTC/LYSA/FIL Intergroup H10 trial assessed whether omitting involved-node radiotherapy would affect progression-free survival in patients with negative early positron-emission tomography (PET) scans after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared with...
Phase III Study: Crizotinib Prolongs Progression-Free Survival in Previously Untreated ALK-Positive Advanced NSCLC
In the phase III PROFILE 1014 study, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori) was found to significantly prolong progression-free survival in previously untreated patients with ALK-positive advanced nonsquamous non–small cell lung cancer (NSCLC) compared with...
PARP Inhibitor Veliparib Might Benefit Women With Resistant Gynecologic Cancers and BRCA Mutation
Preliminary research suggests that a targeted oral agent may improve outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies. According to a phase II study presented at the Society of Gynecologic...
Long-Term Follow-up Shows Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma
Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...
Study Finds Oncologists Have Mixed Attitudes on the Use of Genomic Testing
While many cancer researchers believe that predictive somatic genomic testing holds the potential to usher in the era of precision medicine for patients with cancer, research by Gray et al suggests that not all physicians are eager to embrace the technology. The variation in attitudes was in part...
Women With BRCA1 Mutations May Still Be at Risk for Rare Types of Uterine Cancer After Preventive Salpingo-Oophrectomy
Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer held ...
Audit of NHS Breast Cancer Screening Programme Reveals Significant Variations Between Hospitals in Treatment Outcomes for DCIS
Analysis of data from the UK NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ (DCIS) between UK hospitals. Dr. Jeremy Thomas, a consultant pathologist at the Western General Hospital, Edinburgh, told the 9th...
Harms Outweigh Benefits for Women Aged 70 and Over in National Breast Cancer Screening Programs
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the number of cancers detected at advanced stages, according to new research from The Netherlands. Instead, researchers told attendees at the 9th European Breast Cancer Conference that...
Investigational Cancer Vaccine Shows Renewed Potential in Non–Small Cell Lung Cancer
Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic agent cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not...
Obesity and Diabetes Have Adverse Effects on Outcomes Across Breast Tumor Types, Should Be Taken Into Account When Planning Treatment
Both obesity and diabetes have adverse effects on outcomes in breast cancer patients who receive neoadjuvant chemotherapy, according to research presented at the 9th European Breast Cancer Conference. Although a high body mass index (BMI) is known to have a negative impact on cancer development and ...
Socioeconomic Disparities in Mortality After Cancer Surgery Reflect Higher Failure-to-Rescue Rates in Hospitals Treating More Low-Income Patients
Although it has been found that lower socioeconomic status is associated with higher operative mortality, the factors explaining this disparity have not been clearly defined. In a study of major cancer surgery reported in JAMA Surgery, Reames et al found that hospitals with the highest proportion...
Analysis of SWOG Trials Indicates No Survival Difference After 1 Year in Cancer Patients Treated In vs Out of Clinical Trials
In a study reported in the Journal of the National Cancer Institute, Unger et al evaluated whether cancer patients from SWOG clinical trials were similar to nontrial patients in baseline characteristics and survival. They found that, overall, trial participation in standard treatment arms did not...
Regular Physical Activity Reduces Breast Cancer Risk Irrespective of Age or Weight
Participating in athletic activities for more than an hour a day reduces the risk of breast cancer, and this applies to women of any age and any weight, regardless of geographic location, according to research presented at the 9th European Breast Cancer Conference in Glasgow. Compared with the...
Genetic Testing May Improve Selection of Women With Estrogen Receptor–Positive Breast Cancer for 10 vs 5 Years of Hormonal Therapy
Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen-responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than 5 years. Women who had...
Postmastectomy Radiotherapy Benefits Women With Breast Cancer That Has Spread to One to Three Lymph Nodes
Women whose breast cancer has spread to just a few lymph nodes under their arm are less likely to have their disease recur or to die from it if they have radiotherapy after mastectomy, according to new research presented today at the European Breast Cancer Conference in Glasgow and published in The ...
